Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
992.28B
Market cap992.28B
Price-Earnings ratio
50.94
Price-Earnings ratio50.94
Dividend yield
0.56%
Dividend yield0.56%
Average volume
4.93M
Average volume4.93M
High today
$1,055.55
High today$1,055.55
Low today
$1,026.25
Low today$1,026.25
Open price
$1,030.79
Open price$1,030.79
Volume
3.57M
Volume3.57M
52 Week high
$1,055.55
52 Week high$1,055.55
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 992.28B, Eli Lilly(LLY) trades at $1,047.00. The stock has a price-to-earnings ratio of 50.94 and currently yields dividends of 56.3%.

During the trading session on 2025-11-19, Eli Lilly(LLY) shares reached a daily high of $1,055.55 and a low of $1,026.25. At a current price of $1,047.00, the stock is +2.0% higher than the low and still -0.8% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 3.57M, versus its average volume of 4.93M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,055.55 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,055.55 and a low of $623.78.

LLY News

TipRanks 5h
Will Eli Lilly Stock Split? Rumors Are Swirling.

Rumors are swirling that pharmaceutical company Eli Lilly (LLY) will be the next major company to split its stock. TipRanks Black Friday Sale Claim 60% off Ti...

Barchart 8h
This Blue-Chip Stock Is a Heavy Weight in Weight-Loss Drugs

Eli Lilly (LLY) stands out for its diversified pharmaceutical portfolio, robust pipeline, and strategic acquisitions that are fueling growth. LLY has strong te...

The Motley Fool 9h
Stock Split Watch: Could This Unstoppable Growth Stock Be Next?

Don't wait for a stock split to buy the stock, though. Eli Lilly (LLY +1.03%) has had a tumultuous year. The pharmaceutical giant lagged the market for much of...

Stock Split Watch: Could This Unstoppable Growth Stock Be Next?

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
22.6%
Sell
3.2%

More LLY News

TipRanks 10h
Eli Lilly price target raised to $1,182 from $1,038 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on Eli Lilly (LLY) to $1,182 from $1,038 and keeps a Buy rating on the shares. The firm is po...

Nasdaq 12h
Eli Lilly To Open Lilly Gateway Labs Site In Philadelphia

(RTTNews) - Eli Lilly and Company (LLY) announced plans to open a new Lilly Gateway Labs site in Philadelphia. The new Gateway Labs site will occupy 44,000 squa...

Eli Lilly To Open Lilly Gateway Labs Site In Philadelphia
Nasdaq 13h
Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Key Points Eli Lilly has advanced in the triple-digits over three years, thanks to its weight loss drug portfolio. The following two biotech companies, due to...

Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.
The Wall Street Journal 1d
Lilly Stock Continues Its Winning Ways

Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lil...

Lilly Stock Continues Its Winning Ways
Simply Wall St 1d
Are Direct-to-Consumer Channels Reinforcing Eli Lilly’s Competitive Edge in the Obesity Market?

Mangoceuticals, Inc. recently announced the launch of MangoRx Direct and PeachesRx Direct programs, offering direct access to Eli Lilly's Zepbound and Novo Nord...

Are Direct-to-Consumer Channels Reinforcing Eli Lilly’s Competitive Edge in the Obesity Market?
MarketWatch 1d
Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Eli Lilly’s weight-loss drug Zepbound is on track to be the world’s top-selling drug, and Lilly is inching closer to a $1 trillion market cap. Biopharma is bac...

Why biotech and drug stocks are on the mend even though the rest of the market is hurting
Nasdaq 1d
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?

Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to $100 billion by 2030. New...

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.